ORLANDO -- Tirzepatide (Zepbound) improved symptoms of moderate-to-severe obstructive sleep apnea (OSA) in people with obesity, regardless of positive airway pressure (PAP) use, the phase III ...

Tirzepatide (Zepbound) injections reduced sleep apnea severity among patients with obesity, regardless of positive airway pressure (PAP) use, according to topline data from two phase III trials ...

Tirzepatide improved obstructive sleep apnea symptoms compared with placebo among adults with obesity, according to results from the SURMOUNT-OSA trials.After 1 year of treatment, patients ...

ORLANDO, Fla., June 21, 2024 /PRNewswire/ -- Today, findings from the SURMOUNT-OSA, a study of tirzepatide in patients with obstructive sleep apnea (OSA) and obesity, were announced, revealing ...

ORLANDO — The GIP/GLP-1 dual agonist tirzepatide reduced symptoms of obstructive sleep apnea and improved multiple cardiometabolic markers for adults with obesity and obstructive sleep apnea ...

How GLP-1 Agonists Might Help With Sleep Apnea. Both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are GLP-1 agonists, which are medications that help to lower blood sugar ...

“Tirzepatide can also target specific underlying mechanisms of sleep apnea, potentially leading to more personalized and effective treatment,” he added. “It means we can offer an innovative solution, ...

Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials ...

Tirzepatide, the medicine found in the drugs Zepbound and Mounjaro, reduced the severity of sleep apnea and other measures in patients who had obesity and took the medication for a year.

Across both trials, tirzepatide was clearly superior to placebo at tamping down apnea by the end of the study period. On average, the drug reduced the frequency of these episodes by up to two ...